uniQure N.V. (QURE) Analysts See $-0.68 EPS

March 15, 2018 - By Marguerite Chambers

 uniQure N.V. (QURE) Analysts See $ 0.68 EPS

Analysts expect uniQure N.V. (NASDAQ:QURE) to report $-0.68 EPS on March, 21.They anticipate $0.42 EPS change or 161.54 % from last quarter’s $-0.26 EPS. After having $-0.40 EPS previously, uniQure N.V.’s analysts see 70.00 % EPS growth. The stock decreased 10.95% or $2.75 during the last trading session, reaching $22.36. About 729,774 shares traded or 81.10% up from the average. uniQure N.V. (NASDAQ:QURE) has declined 52.65% since March 15, 2017 and is downtrending. It has underperformed by 69.35% the S&P500.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 13 analysts covering uniQure N.V. (NASDAQ:QURE), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. uniQure N.V. had 28 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 27 by Chardan Capital Markets. Oppenheimer maintained the shares of QURE in report on Monday, September 21 with “Outperform” rating. The firm has “Buy” rating given on Monday, November 30 by Roth Capital. The rating was maintained by Piper Jaffray on Friday, August 28 with “Overweight”. The stock has “Buy” rating by Janney Capital on Tuesday, December 1. The stock has “Buy” rating by WallachBeth Capital on Friday, August 7. WallachBeth Capital maintained uniQure N.V. (NASDAQ:QURE) rating on Friday, August 28. WallachBeth Capital has “Buy” rating and $33 target. Janney Capital initiated uniQure N.V. (NASDAQ:QURE) on Wednesday, January 3 with “Buy” rating. The company was maintained on Tuesday, December 1 by WallachBeth Capital. The rating was maintained by Piper Jaffray on Monday, September 21 with “Buy”.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $686.93 million. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More news for uniQure N.V. (NASDAQ:QURE) were recently published by: Streetinsider.com, which released: “Form 8-K uniQure NV For: Mar 14” on March 14, 2018. Seekingalpha.com‘s article titled: “uniQure reports FY results” and published on March 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.